

Yoshiaki Ohtsu

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7417482/yoshiaki-ohtsu-publications-by-citations.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23

papers

362

citations

8

h-index

18

g-index

25

ext. papers

426

ext. citations

3

avg, IF

3.02

L-index

| # | Paper | IF | Citations |
|----|---|-----|-----------|
| 23 | Pharmacokinetic Drug Interaction Studies with Enzalutamide. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 1057-69 | 6.2 | 88 |
| 22 | Clinical Pharmacokinetic Studies of Enzalutamide. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 1043-55 | 6.2 | 83 |
| 21 | Stability: recommendation for best practices and harmonization from the Global Bioanalysis Consortium Harmonization Team. <i>AAPS Journal</i> , 2014 , 16, 392-9 | 3.7 | 39 |
| 20 | Validation of a method for quantifying enzalutamide and its major metabolites in human plasma by LC-MS/MS. <i>Bioanalysis</i> , 2014 , 6, 737-44 | 2.1 | 27 |
| 19 | ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity. <i>International Immunopharmacology</i> , 2011 , 11, 732-9 | 5.8 | 25 |
| 18 | Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 1339-46 | 5.9 | 23 |
| 17 | Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies. <i>Advances in Therapy</i> , 2017 , 34, 2625-2637 | 4.1 | 13 |
| 16 | Therapeutic potential of ASP3258, a selective phosphodiesterase 4 inhibitor, on chronic eosinophilic airway inflammation. <i>Pharmacology</i> , 2012 , 90, 223-32 | 2.3 | 10 |
| 15 | Quantification of ASP2151 in Human Plasma and Urine: A Pitfall Associated with Supersaturation of Analyte in Urine. <i>Chromatographia</i> , 2017 , 80, 217-227 | 2.1 | 7 |
| 14 | Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults. <i>Advances in Therapy</i> , 2017 , 34, 2466-2480 | 4.1 | 7 |
| 13 | Absorption, Distribution, Metabolism, and Excretion of the Androgen Receptor Inhibitor Enzalutamide in Rats and Dogs. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017 , 42, 611-626 | 2.7 | 7 |
| 12 | Determination of the Androgen Receptor Inhibitor Enzalutamide and its Metabolites in Animal Plasma and Brain Homogenates Using LC-MS/MS and its Application to Pharmacokinetic Studies. <i>Chromatography</i> , 2015 , 36, 115-122 | 1.2 | 7 |
| 11 | Absorption, Distribution, Metabolism, and Excretion of the Novel Helicase-Primase Inhibitor, Amenamevir (ASP2151), in Rodents. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2018 , 43, 693-706 | 2.7 | 5 |
| 10 | Regulated bioanalysis of conformers - A case study with ASP2151 in dog plasma and urine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015 , 997, 56-63 | 3.2 | 3 |
| 9 | Incurred sample stability of ASP3258 in the presence of its acyl glucuronide. <i>Journal of Applied Bioanalysis</i> , 2017 , 3, 34-42 | 1.3 | 3 |
| 8 | Biomarker assay validation for clinical trials: a questionnaire survey to pharmaceutical companies in Japan. <i>Bioanalysis</i> , 2019 , 11, 55-60 | 2.1 | 3 |
| 7 | Analytical method validation for biomarkers as a drug development tool: points to consider. <i>Bioanalysis</i> , 2021 , 13, 1379-1389 | 2.1 | 3 |

| | | | |
|---|--|-----|---|
| 6 | Determination of ASP3258, a novel phosphodiesterase type 4 inhibitor, in rat plasma by high-performance liquid chromatography with fluorescence detection and its application to pharmacokinetic study. <i>Biomedical Chromatography</i> , 2015 , 29, 161-3 | 1.7 | 2 |
| 5 | Absorption, distribution, metabolism and excretion of novel phosphodiesterase type 4 inhibitor ASP3258 in rats. <i>Biopharmaceutics and Drug Disposition</i> , 2015 , 36, 34-48 | 1.7 | 1 |
| 4 | Bioanalytical Quantification of Therapeutic Antibodies by Liquid Chromatography/mass Spectrometry. <i>Chromatography</i> , 2018 , 39, 7-19 | 1.2 | 1 |
| 3 | An Open-Label, Single-Dose, Human Mass Balance Study of Amenamevir in Healthy Male Adults. <i>Clinical Pharmacology in Drug Development</i> , 2019 , 8, 595-602 | 2.3 | 1 |
| 2 | Intersubject and Intrasubject Variability of Potential Plasma and Urine Metabolite and Protein Biomarkers in Healthy Human Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 397-405 | 6.1 | 1 |
| 1 | Highlights of the 12th Japan Bioanalysis Forum Symposium. <i>Bioanalysis</i> , 2021 , 13, 1653-1657 | 2.1 | |